Alnylam Pharmaceuticals, Inc. Stock Performance
as on October 25, 2025 at 1:29 am IST
Day's Low
Day's High
$459.38$469.29
0.80%
Downside
1.34%
Upside
52 Week's Low
52 Week's High
$205.87$495.5555.54%
Downside
7.01%
Upside
Alnylam Pharmaceuticals, Inc. share price movements today
- Previous Close
- $464.00
- Open
- $468.68
- Volume
- 749.7K
- Day's Low - High
- $459.38 - $469.29
- 52 Week Low - High
- $205.87 - $495.55
Alnylam Pharmaceuticals, Inc. Historical Returns
- 1 Month Return
- + 3.81 %
- 3 Month Return
- + 40.94 %
- 1 Year Return
- + 62.69 %
- 3 Year Return
- + 138.88 %
- 5 Year Return
- + 265.42 %
Alnylam Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$60.7B
EPS (TTM)
4.2471
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-505.15
Industry PE ratio
20.234025974025975
PEG Ratio
-0.49
EBITDA
-123.7M
Revenue (TTM)
2.5B
Profit Margin
-12.96%
Return On Equity TTM
-257.83%
Alnylam Pharmaceuticals, Inc. Stock Valuation
Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Alnylam Pharmaceuticals, Inc. in the last 5 years
Lowest (-115.71x)
September 30, 2024
Today (-505.15x)
October 27, 2025
Industry (20.23x)
October 27, 2025
Highest (-17.43x)
December 31, 2020
Today’s Price to Earnings Ratio: -505.15x
Alnylam Pharmaceuticals, Inc. vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $60.7B | 265.42% | -505.15 | -12.96% | |
| NA | $35.8B | NA | NA | -3.89% | |
| BUY | $108.0B | 98.59% | 29.95 | 31.86% | |
| BUY | $61.3B | -0.78% | 14.55 | 31.37% |
Stock Returns calculator for Alnylam Pharmaceuticals, Inc. Stock including INR - Dollar returns
The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Alnylam Pharmaceuticals, Inc. investment value today
Current value as on today
₹1,67,639
Returns
₹67,639
(+67.64%)
Returns from Alnylam Pharmaceuticals, Inc. Stock
₹62,564 (+62.56%)
Dollar Returns*
₹5,074 (+5.07%)
Analyst Recommendation on Alnylam Pharmaceuticals, Inc. Stock
Based on 34 analysts
70.59%
Buy
29.41%
Hold
0.00%
Sell
Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $459.35
Alnylam Pharmaceuticals, Inc. Share Price Target
Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..
What analysts predicted
-0.81%DOWNSIDE
Target Price
$459.35
Current Price
$463.08
Analyzed by
34 Analysts
Target
$459.35
Alnylam Pharmaceuticals, Inc. target price $459.35, a slight downside of -0.81% compared to current price of $463.08. According to 34 analysts rating.
Alnylam Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest
Search interest for Alnylam Pharmaceuticals, Inc. Stock has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Alnylam Pharmaceuticals, Inc. Quarterly Profit & Loss
All numbers in Millions USD
Alnylam Pharmaceuticals, Inc. Annual Profit & Loss
All numbers in Millions USD
Alnylam Pharmaceuticals, Inc. Quarterly Cash Flow
All numbers in Millions USD
Alnylam Pharmaceuticals, Inc. Annual Cash Flow
All numbers in Millions USD
Alnylam Pharmaceuticals, Inc. News & Key Events
Today's Timeline - 23 October
Thu, 07:30 PM
-Alnylam Pharmaceuticals expected to report over 100% revenue growth and earnings of $1.67 per share on October 30.
Insights on Alnylam Pharmaceuticals, Inc.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Alnylam Pharmaceuticals, Inc. has experienced consistent revenue growth over the last four quarters. The revenue increased from $500.91 million to $773.68 million. This represents an average increase of 13.0% per quarter.
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ALNY has outperformed top 5 stocks with highest market-cap in its industry
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ALNY has outperformed top 5 stocks with highest market-cap in its industry
NEGATIVE IMPACTProfit Down
Alnylam Pharmaceuticals, Inc. has seen a decline in its net profit over the last two quarters. The net profit decreased from -$57.47 million to -$66.27 million, which means the company is losing more money. This represents an average decrease of 15.3% in net profit each quarter.
- NEGATIVE IMPACT
Price Dip
In the last 7 days, ALNY stock has moved down by -5.7%
About Alnylam Pharmaceuticals, Inc.
| Organisation | Alnylam Pharmaceuticals, Inc. |
| Headquarters | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| E-voting on shares | Click here to vote |
Key Management of Alnylam Pharmaceuticals, Inc.
Name | Title |
|---|---|
Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Mr. Bryan Andrew Supran J.D. | Chief Legal Officer |
Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP |
Dr. Pushkal P. Garg M.D. | EVP of Development & Medical Affairs and Chief Research & Dev. Officer |
Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
Ms. Christine Regan Akinc | Chief Corporate Communications Officer |
Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
FAQs
What is Alnylam Pharmaceuticals, Inc. share price today?
Alnylam Pharmaceuticals, Inc. share price today is $463.08 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $469.29 and a low of $459.38.
What is the 52 week high and 52 week low for Alnylam Pharmaceuticals, Inc. share?
Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $495.55 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $463.08,which is 6.55% down from its 52 week high and 124.94% up from its 52 week low.
What is Alnylam Pharmaceuticals, Inc.'s market capitalisation today?
Alnylam Pharmaceuticals, Inc. market capitalisation is $0.06T as on .
How to invest in Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Alnylam Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alnylam Pharmaceuticals, Inc. Shares that will get you 0.0032 shares as per Alnylam Pharmaceuticals, Inc. share price of $463.08 per share as on October 25, 2025 at 1:29 am IST.
What is the minimum amount required to buy Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?
Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹88.189 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.89 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $463.08 as on October 25, 2025 at 1:29 am IST, you will get 0.0216 shares of Alnylam Pharmaceuticals, Inc.. Learn more about
fractional shares .
What are the returns that Alnylam Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?
Alnylam Pharmaceuticals, Inc. stock has given 265.42% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?